oral glp 1 agonist for weight loss Top GLP-1 Agonists Balance Efficacy, Safety Novel oral GLP-1 receptor agonist

In research, a GHRH analog combined with a growth-hormone secretagogue is examined for how the two pathways interact

In a phase 2 dose-finding trial, once-weekly Cagrilintide produced clinically meaningful weight loss about 10.8% at the 4.5 mg dose over 26 weeks with gastrointestinal effects the most common adverse events [1]

Additionally, clinical studies are also required to understand whether there is correlation of serum or synovial fluid butyrate levels with ferroptosis markers (e.g., GPX4, ROS) or disease severity in OA patients, and the chondroprotective efficacy of butyrate supply to beneficial bacteria by probiotics or dietary fibers

doi: 10.1093/ajcn/83.2.191 41 AknUzunakmakTKAltunkalemNTznY